NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation concerns whether the board of directors of Blue have breached their fiduciary duties to the company. Blue is a biot ...

Montreal, Quebec--(Newsfile Corp. - June 25, 2024) - Blue Thunder Mining Inc. (TSXV: BLUE) ("Blue Thunder" or the "Company") announces that Alain Lévesque will be joining the Company's management team as CFO effective June 25, 2024, replacing Robert Boisjoli who will be resigning his position as CFO effective the same date in order to devote his full attention to other business interests. Mr. Lévesque has 20 years of experience in the field of financial reporting and the management of corporations includin ...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Medallion Financial Corp. (NASDAQ: MFIN) (“Medallion” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recommended that Medallion shareholders vote on the BLUE proxy card “FOR” ONLY the candidates nominated by the Board of Directors, Robert M. Meyer and David L. Rudnick and “FOR” the advisory vote on the compensation of the Company’s named executive officers in connection with the Company’s 2024 Ann ...

Montreal, Quebec--(Newsfile Corp. - June 4, 2024) - Blue Thunder Mining Inc. (TSXV: BLUE) ("Blue Thunder" or the "Company") announces that as of its Annual General Meeting to be held on June 6, 2024, and subject to approval at that meeting, the Company will change its name to Orbec Gold Mines Inc. ("Orbec"). The ticker will remain "BLUE" for simplicity and ease of trading as well as for legacy reasons. In addition, the Company is relocating its headquarters to 2000 rue de l'Éclipse, Suite 500, Brossard, Qu ...

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerPost thisDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in the biopharmaceutical industry leading clinical development of multiple medicines across various therapeutic areas. At Chinook Therapeutics, she advanced the pipeline as Senior VP of Product Development and Strategy, leading to a $3.2 billion acquisition by Novartis. Previously, she was VP of Global Clinical Deve ...

NEW YORK, May 30, 2024 /PRNewswire/ -- Blue Owl Capital Inc. ("Blue Owl") (NYSE: OWL) today announced the pricing of the offering of $250,000,000 of 6.250% Senior Notes due 2034 (the "notes") by Blue Owl Finance LLC, its indirect subsidiary, at an issue price of 100.355%, plus accrued interest, if any, from April 18, 2024. The notes are being offered as additional notes under the same indenture as the previously issued $750,000,000 aggregate principal amount of its 6.250% Senior Notes due 2034 and will be t ...

Core Viewpoint - A class action lawsuit has been filed against bluebird bio, Inc. regarding allegations of securities fraud and unlawful business practices [1] Group 1: Company Developments - On December 8, 2023, bluebird received FDA approval for its drug Lyfgenia (lovotibeglogene autotemcel) for treating sickle cell disease in patients aged 12 and older, but the approval included a black box warning for hematological malignancies due to two patients developing acute myeloid leukemia during clinical trials [2] - Following the announcement of the black box warning, bluebird's stock price dropped by $1.95 per share, or 40.54%, closing at $2.86 per share on the same day [2] Group 2: Legal Context - The class action lawsuit allows shareholders who purchased bluebird securities during the Class Period to request to be appointed as Lead Plaintiff by May 28, 2024 [1] - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, having recovered billions in damages for class members over its 85-year history [3]

NEW YORK, May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bluebird-bio-loss-submission-form/?id=80713&from=4CLASS PERIOD: April 24, 2023 to Decem ...

LOS ANGELES, May 16, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE).Class Period: April 24, 2023 – December 8, 2023Lead Plaintiff Deadline: May 28, 2024If you wish to serve as lead plaintiff of the bluebird lawsuit, you can submit your contact information at www.glancylaw.com/cases/bluebird-bio-Inc-1/. You can al ...

It won't be easy for the company to bounce back.Being a highly innovative company isn't a sufficient condition for success in the biotech industry. Bluebird Bio (BLUE), a small-cap gene-editing specialist, is a good example of this. Though the company has developed groundbreaking therapies, the stock has significantly lagged the market in recent years. Still, if Bluebird Bio can turn things around, the company could deliver explosive returns to investors who initiate a position today. Is Bluebird Bio worth ...